Showing results (51-60 of 62) with videos related to
Sort By:
Pageof 7
Clinical Pharmacology and Therapeutics|March 1, 1995
The effect of zileuton on antipyrine and indocyanine green dispositionJ V St Peter, R A Braeckman, G R Granneman, et al.Clinical Pharmacokinetics|January 1, 1995
The pharmacokinetic and pharmacodynamic interactions between the 5-lipoxygenase inhibitor zileuton and the cyclo-oxygenase inhibitor naproxen in human volunteersW M Awni, R A Braeckman, J H Cavanaugh, et al.Journal of Clinical Pharmacology|April 1, 1995
Pharmacokinetics of bepridil and two of its metabolites in patients with end-stage renal diseaseW M Awni, C E Halstenson, R K Nayak, et al.Clinical Pharmacokinetics|January 1, 1995
The effect of mild or moderate hepatic impairment (cirrhosis) on the pharmacokinetics of zileutonW M Awni, J H Cavanaugh, R A Braeckman, et al.Antimicrobial Agents and Chemotherapy|November 1, 1991
Isepamicin disposition in subjects with various degrees of renal functionC E Halstenson, J S Kelloway, M B Affrime, et al.European Journal of Clinical Pharmacology|January 29, 1999
Pharmacokinetics of a novel 5-lipoxygenase inhibitor (ABT-761) in pediatric patients with asthmaS L Wong, G L Kearns, J P Kemp, et al.Antimicrobial Agents and Chemotherapy|November 1, 1991
Pharmacokinetics of ceftibuten-cis and its trans metabolite in healthy volunteers and in patients with chronic renal insufficiencyJ S Kelloway, W M Awni, C C Lin, et al.Clinical Pharmacology and Therapeutics|January 1, 1988
Pharmacokinetics and pharmacodynamics of codeine in end-stage renal diseaseD R Guay, W M Awni, J W Findlay, et al.Journal of Clinical Pharmacology|May 1, 1997
Pharmacokinetics of zileuton and its metabolites in patients with renal impairmentW M Awni, S Wong, S Y Chu, et al.Journal of Clinical Pharmacology|December 1, 1987
Pharmacokinetics of codeine after single- and multiple-oral-dose administration to normal volunteersD R Guay, W M Awni, C E Halstenson, et al.Pageof 7